title: Intralesional verapamil prevents the progression of Peyronie's disease.
abstract: OBJECTIVE
  To define the impact of intralesional verapamil injection therapy on penile deformity in men with Peyronie's disease.
  
  
  METHODS
  Patients underwent a total of 6 intralesional injections of verapamil. Penile deformity was assessed at baseline and 3 months after the last intralesional injection of verapamil during penile erection after the administration of intracavernosal medication. Measurement was recorded using a goniometer at maximum penile rigidity. Endpoints included change in magnitude of curvature, stretched penile length, penetration ability, and resolution of pain.
  
  
  RESULTS
  Ninety-four consecutive patients met all inclusion criteria. Mean (+/- standard deviation) patient age and duration of Peyronie's disease at time of baseline deformity assessment were 44 +/- 18 years and 5.2 +/- 2.7 months, respectively. At baseline 86% had dorsal and 14% lateral curvature. The mean curvature and stretched flaccid length were 50 degrees +/- 28 degrees and 12.6 +/- 3.1 cm, respectively. At the follow-up evaluation, patients were 5.2 +/- 1.8 months after their last ILV injection and were 11.7 +/- 4.2 months after the onset of Peyronie's disease. Eighteen percent of patients had improvement of curvature, 60% were unchanged, and 22% worsened. Pain resolved in 100% of patients.
  
  
  CONCLUSIONS
  In response to intralesional verapamil, a minority of men experienced improvement in penile deformity; however, the majority of patients had stabilization of their deformity. This information may permit clinicians to give realistic expectations to patients considering intralesional verapamil therapy.
authors.affiliation: Department of Urology, Weill Medical College of Cornell University, New York, New York 10021, USA.
authors.forename: Nelson E
authors.initials: NE
authors.lastname: Bennett
authors.forename: Patricia
authors.initials: P
authors.lastname: Guhring
authors.forename: John P
authors.initials: JP
authors.lastname: Mulhall
mesh_terms: D000328:Adult; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D010411:Penile Induration / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage*; D014700:Verapamil / Q000008:administration & dosage*
chemical_list: D014665:Vasodilator Agents; D014700:Verapamil